





Crystallization and disorder of the polytypic α1 and α2 




Manuscript ID: CE-ART-01-2015-000050.R1 
Article Type: Paper 
Date Submitted by the Author: 23-Feb-2015 
Complete List of Authors: Upadhyay, Pratik; University of Copenhagen, Department of Pharmacy 






Cite this: DOI: 10.1039/c0xx00000x 
www.rsc.org/xxxxxx 
Dynamic Article Links ►
ARTICLE TYPE
 
This journal is © The Royal Society of Chemistry [year] [journal], [year], [vol], 00–00  |  1 
Crystallization and disorder of the polytypic α1 and α2 
polymorphs of piroxicam 
Pratik P. Upadhyaya and Andrew D. Bond*a,b 
Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX 
DOI: 10.1039/b000000x 5 
Polymorphism of the active pharmaceutical ingredient piroxicam, C15H13N3O4S, is investigated with an 
aim to clarify the identity and crystallization conditions of the α1 and α2 polymorphs. The structures are 
polytypic, containing identical 2-dimensional layers, with different symmetry relationships between the 
layers. The α1 structure is orthorhombic and non-centrosymmetric (space group type Pca21), while the α2 
structure is monoclinic and centrosymmetric (space group type P21/c). α2 can be crystallized by 10 
evaporation from ethanol at 25°C, while α1 is obtained by crystallization from the same solvent at 4°C. 
The polytypic relationship provides a suitable condition for order-disorder phenomena to be observed in 
single crystals. Intermolecular interaction energies calculated using the PIXEL method suggest that the 
centrosymmetric interlayer regions in α2 involving the pyridyl groups are more stabilising than the 
corresponding non-centrosymmetric interlayer regions in α1. This is consistent with observations of 15 
inversion twinning in non-centrosymmetric α1 crystals. The interlayer regions involving the 
benzothiazine groups have very similar interaction energies in the two structures.  
Introduction 
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) 
belonging to the class of oxicam.1 Crystalline piroxicam is known 20 
to show polymorphism, which has been studied quite extensively 
since its discovery. The compound is established to crystallize in 
several anhydrous forms,2–5 and one monohydrate form.6 For the 
anhydrous compound, there are currently eight entries in the 
Cambridge Structural Database (CSD; Nov. 2013 release plus 25 
updates), which fall into four structural groups (Table 1). As is 
often the case for well-studied compounds, the nomenclature of 
the polymorphs in the primary literature is inconsistent. The 
situation up to 2004 was summarised in a helpful article by Sheth 
et al.4 Form I (also called the β form) was the first structure to be 30 
described (CSD: BIYSEH),2 and it crystallizes commonly by 
slow cooling from various solvents. Form III was observed by 
Vrečer et al. in 2003,7 and has been obtained by rapid pouring of 
hot saturated solutions onto dry ice7 or by spray drying.5 The 
crystal structure of form III was determined from powder X-ray 35 
diffraction (PXRD) data in 2012 (BIYSEH07).5 
 The subject of this paper is the polymorph originally labelled 
as the α form, and later (ambiguously) re-labelled as form II.8 An 
orthorhombic crystal structure was first reported from single-
crystal data in 1988 by Reck et al. (BIYSEH02).3 In that paper, 40 
the authors noted that Weissenberg photographs contained diffuse 
strips and a few weak additional reflections, which led them to 
propose an order-disorder (OD) model,9 with the orthorhombic 
form being one maximum-degree-of-order (MDO) structure. On 
the basis of the OD model, a monoclinic structure corresponding 45 
to a second MDO structure was deduced.10 The orthorhombic and 
monoclinic structures were labelled α1 and α2, respectively, and 
they are polytypes.11 Reck et al. initially showed the existence of 
α1 and α2 by comparing to measured PXRD patterns, and they 
noted that the α1 and α2 structures frequently appear in varying 50 
ratios in bulk samples. A single-crystal structure for α2 was later 
determined by Vrečer et al. (BIYSEH06),7 where the authors 
refer to it as form II. 
 
Scheme 1 Molecular structure of piroxicam 55 
 Although the polytypic relationship and probable disordered 
nature of α1 and α2 was described by Reck et al. in 1990,
10 the 
identity of the polymorphs does not seem to be clear in the 
subsequent literature. This is possibly because of the close 
structural relationship between the polytypes or perhaps because 60 
of the introduction of the ambiguous form II label by Vrečer et 
al.7 The summary article by Sheth et al. is unclear on this point: it 
states that “…form II has also been named α, α1, α2…”,
4 which 
indicates that all three α labels refer to the same “form II”. In this 
article, we aim to clarify the existence and identity of the 65 
piroxicam polymorphs α1 and α2, by describing their polytypic 
relationship and by identifying reproducible crystallization 
conditions for both. The structural situation is comparable to that 
described for aspirin, which exhibits intergrowth polymorphism 
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on account of the polytypic relationship between forms I and 
II.12,13 A similar situation has also been shown for felodipine, 
where crystals reported to be form II comprise domains of two 
polytypes.14 In this paper, we retain the original piroxicam α1/α2 
notation of Reck et al. for consistency with the original work. 5 
Table 1 CSD entries for anhydrous piroxicam 
Polymorph CSD Refcode Symmetry and approximate 
unit-cell parameters (Å, °) 
Ref. 
    
Form I 






a = 7.1, b = 15.1, c = 13.9, 





    
α1 BIYSEH02 Orthorhombic, Pca21 
a = 11.8, b = 17.4, c = 7.0 
[3] 




a = 17.6, b = 11.9, c = 7.0 
β = 97 
[4] 
[7] 
    
Form III BIYSEH07 Triclinic, P–1 
a = 8.0, b = 10.1, c = 10.5 




Fig. 1 Simulated powder X-ray diffraction patterns (CuKα1 radiation, λ = 
1.5406 Å) for piroxicam structures in the CSD. All patterns are based on 10 
crystal structures determined at room temperature. 
Materials and Methods 
Piroxicam (USP32) was purchased from Chr. Olesen 
Pharmaceuticals A/S (Gentofte, Denmark) and was found to be 
Form I by PXRD. All solvents used were of HPLC grade with 15 
purity ≥99.8 %. 
Crystallization experiments 
Crystallization experiments were set up at concentrations 2.0, 5.0, 
10.0 and 15.0 mg/mL in various solvents as listed in Table 2. The 
samples at 2.0 mg/mL were sonicated for 10 mins in order to 20 
obtain a clear solution. At 5.0 mg/mL in methanol, ethanol, 
acetonitrile and n-propanol, a suspension was formed upon 
sonication, which was further heated to 50°C to obtain a clear 
solution. At 10.0 and 15.0 mg/mL, all samples except for acetone, 
dichloromethane, dimethylsulfoxide and dimethylacetamide 25 
formed a suspension and were heated to obtain a clear solution. 
All hot solutions were cooled slowly to room temperature 
(preventing rapid crashing) and left to evaporate at either 25 or 
4°C. 
X-Ray Diffraction 30 
Single-crystal X-ray diffraction data were collected on a Bruker 
D8-QUEST instrument, equipped with a PHOTON-100 detector 
and an Incoatec IµS microsource (CuKα radiation; λ = 1.5418 Å) 
at 298 K. Data collection and reconstruction of precession images 
were carried out using the APEX2 package.16 Powder X-ray 35 
diffraction data were collected on a Panalytical X’Pert Pro 
instrument, equipped with a PIXcel detector using non-
monochromated CuKα radiation (λ = 1.5418 Å). The sample was 
placed in a zero-background Si holder and measured in reflection 
geometry with sample spinning. Samples were ground thoroughly 40 
before mounting in an effort to minimise preferred orientation. 
The PXRD patterns were fitted by Pawley refinement using 
TOPAS Academic,17 starting from the unit-cell parameters of 
BIYSEH02 (α1) and BIYSEH05 (α2). 
Computational Methods 45 
Energy minimisation of the crystal structures was carried out 
using the CASTEP module18 in Materials Studio.19 The starting 
structures were BIYSEH05 (α2) and a transformed version of 
BIYSEH02 (α1) as described in the Results and Discussion 
section. The PBE functional was applied20 with a plane-wave cut-50 
off energy of 520 eV and a dispersion correction according to 
Grimme.21 All other parameters were set to the “fine” defaults 
within Materials Studio; full details are included in the ESI†. All 
atomic coordinates and unit-cell parameters were optimized. 
Results and Discussion 55 
Crystallization studies 
We have crystallized piroxicam under various conditions and 
solvents, as summarized in Table 2, with an emphasis on 
targeting the α1 and α2 forms. Numerous other authors have 
reported piroxicam crystallization results, so the following 60 
discussion compares to the published results where relevant. 
 Michalić et al. were first to describe the crystallization 
behaviour in ethanol in 1982.1 They stated that fast cooling of 
saturated ethanolic solutions leads to the “needle form” whereas 
slow cooling produces the “cubic form”. The “cubic form” is 65 
identifiable as form I, but it is difficult to identify the “needle 
form” conclusively as either α1 or α2. The published PXRD 
pattern matches most closely with α1, but the stated melting point 
(196–198°C) matches with α2 (according to our DSC results). In 
1999, Csóka et al. also obtained “white needle crystals” from 70 
ethanol, with a melting point that indicates α2.
22 We find that 
slow evaporation from ethanol gives initially α2 as needles, but 
that these needles convert to form I over 1–2 weeks on standing 
in the same solution. The α2→I conversion appeared to take place 
more rapidly for the lower solution concentrations (ca 5 mg/mL) 75 
than at the higher concentrations. 
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Table 2 Summary of crystallization results for piroxicam in selected 
solvents and conditions.a Polymorph identity is established by unit-cell 
determination on selected single crystals and by PXRD of the bulk 
 Slow evap. at 25°C Slow evap. at 4°C 
   
Ethanol α2 α1 
Acetone I + α2 α1 
Methanol I + α1 α1 
Isopropyl acetate I + α2 α1 
Ethyl acetate I + α2  
n-Propanol α2  
Acetonitrile I  
Chloroform I  
Toluene I  
Dichloromethane I  
Dimethylsulfoxideb I  
Dimethylacetamideb I  
a All solvents are anhydrous. The presence of water leads readily to 
crystallization of piroxicam monohydrate. 5 
b α2 obtained by crash cooling of hot solutions to room temperature. 
 In 1991, Janik et al. studied the influence of various solvents 
on the crystallization behaviour, and reported that the “α 
structure” crystallized from ethanol, isopropanol, THF, 
acetonitrile and chloroform.23 We find some conflicting results: 10 
we observe that form I crystallizes as large rods from acetonitrile 
or chloroform under slow evaporation at 25°C. However, the 
conclusions of Janik et al. were made solely on the basis of IR 
spectra, without measurement of PXRD patterns, so the 
effectiveness of their polymorph identification may be in doubt. 15 
 Also in 1991, Vrečer et al. produced α1 by crash cooling of 
methanol, ethanol, acetone, n-propanol or chloroform solutions.8 
The identity of α1 is clear from the published DSC traces 
(compared to our DSC traces reported herein), but accompanying 
PXRD data were not reported and the authors did not make any 20 
distinction between α1 and α2. Indeed, they refer to “form II” in 
their 1991 paper for obtained α1 samples, but in 2003 refer again 
to “form II” for samples that are clearly α2. We observe that α1 is 
obtained exclusively and reproducibly by slow evaporation of 
piroxicam solutions in ethanol, methanol, acetone or isopropyl 25 
acetate at reduced temperature (around 4°C). As seen in SEM 
images (Fig. 2), α1 crystallizes as fine needles. The PXRD 
patterns of the bulk crystallized materials (Fig. 3) match well 
with the pattern simulated from BIYSEH02. 
 30 
Fig. 2 SEM image of α1 crystals, showing the fine needle morphology. 
 
Fig. 3 Pawley fits to PXRD patterns (non-monochromated CuKα 
radiation, λ = 1.5418 Å) measured for bulk samples of α1 and α2. Refined 
unit-cell parameters: α1, Pbc21, a = 17.4120(7), b = 11.8350(4), c = 35 
6.9871(5) Å; α2, P21/c, a = 17.6122(10), b = 11.8758(6), c = 6.9571(6) Å, 
β = 97.474(12)°. 
 In summary: we find that α1 can be crystallized reproducibly 
from ethanol, methanol, acetone or isopropylacetate at 4°C, while 
α2 crystallizes from ethanol at 25°C, but undergoes solvent-40 
mediated transformation to form I if left in contact with the 
crystallization solution. 
Crystal structures of α1 and α2 
To enable a direct comparison between the crystal structures of 
α1 and α2, we transform the published structure of BIYSEH02 45 
(α1) using the matrix [0 1 0 / –1 0 0 / 0 0 1] to give unit-cell 
parameters a = 17.4, b = 11.8, c = 7.0 Å in the non-standard space 
group setting Pbc21. H atoms are not included in BIYSEH02, but 
can be unambiguously added in geometrical positions. This 
transformed structure of BIYSEH02 is compared below to the 50 
CSD entry BIYSEH05 (α2). 
 The two structures contain identical layers in the bc planes, but 
the a axis (the long axis) is aligned differently. The orthorhombic 
unit cell of α1 can be transformed to the monoclinic unit cell of 
α2 by application of the transformation matrix [1 0 ⅓ / 0 1 0 / 0 0 55 
1], which corresponds to shearing of the unit cell parallel to the c 
axis, i.e. a(α2) = a(α1) + ⅓c(α1). In projection along the c axis, 
the structures appear identical (Fig. 4). The difference is seen in 
projection along the b axis (Fig. 4). The layers in α1 are related 
by 21 screw axes parallel to c, and by b- and c-glides 60 
perpendicular to the a and b axes, respectively The structure is 
non-centrosymmetric and polar, with all N–CH3 vectors pointing 
in the same direction along the c axis. In the α2 structure, 
inversion centres exist between the layers. The two alternative 
orientations for a given layer are related to each other by a mirror 65 
operation perpendicular to the c axis (Fig. 5). 
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 There are two different interlayer regions: one where the 
pyridyl rings meet (at the upper and lower edges of the unit cell 
drawn in Fig. 4), and one where the benzothiazine ends of the 
molecules meet (at the middle of the unit cell in Fig. 4). In both 
regions, the local intermolecular relationships are mirrored, but 5 
the contacts remain similar. The principal interactions are C—
H···O from the pyridyl and benzothiazine rings to the O atoms of 
the S=O, C=O and C—OH groups. The intermolecular 
interactions and their energies are discussed in more detail 
subsequently. 10 
 
Fig. 4 Unit cells of the α1 and α2 structures. The structures look identical 
in projection along the c axis (left), but different in projection along the b 
axis (right). The consistent layers are in the bc planes (horizontal). α1 is 
non-centrosymmetric and polar (all N–CH3 groups point in the same 15 
direction along c), while α2 is centrosymmetric. H atoms are not shown. 
 
Fig. 5 Overlay of α1 (blue) and α2 (red) showing the mirror relationship 
between the alternative layer orientations. 
Relationship between the diffraction patterns 20 
One of our principal interests with the α1 and α2 piroxicam 
structures is their polytypic relationship and the potential for 
stacking faults and/or intergrowth polymorphism, similar to 
aspirin.12,13 By considering the relationship between the single-
crystal diffraction patterns of the two forms, we consider here 25 
how such phenomena would be observed. With the consistent 
layers in both structures lying in the bc planes, α1 and α2 have 
their a* and b* axes aligned, but not their c* axes. The idealized 
geometry in the plane containing a* and c* is shown in Fig. 6. α1 
has an orthorhombic lattice with c* perpendicular to a*, and 30 
parallel to the c axis in real space (horizontal in Fig. 6). In α2, c* 
makes an angle of ~7° to this direction. The geometry is such that 
the diffraction spots along a* for α2 are offset by one third of the 
lattice spacing for α1. This offset could occur in either direction, 
giving three sets of evenly-spaced diffraction spots along a* (Fig. 35 
6). Since the (idealized) offset between the spots is ⅓a*, the 
lattices come back into coincidence in every third row along c* 
(i.e. l = 0, 3, 6, etc.). This is also expressed by the transformation 
matrix relating the two unit cells: [1 0 ⅓ / 0 1 0 / 0 0 1]. The 
observation of three sets of discrete Bragg spots, as indicated in 40 
Fig. 6, would refer to a situation where the domain sizes of the 
three cases (α1 + α2 in two different orientations related by 180° 
rotation around the c axis) were suitably large. Smaller domain 
sizes, corresponding to more frequent turnover between domains, 
would generate diffuse streaks along a* for l ≠ 0, 3, 6, etc. 45 
 
Fig. 6 Schematic illustration of the idealized geometry for the diffraction 
patterns of α1 and α2 in the a*c* planes. Blue spots correspond to 
orthorhombic α1. Red and green spots correspond to two orientations of 
monoclinic α2, related to each other by 2-fold rotation around the real c 50 
axis (horizontal). The black spots are coincident in all three lattices. 
Single-crystal X-ray diffraction 
Crystals of α1 obtained from ethanol at 4°C were studied by 
single-crystal X-ray diffraction. A representative reconstructed 
precession image for the h1l plane is shown in Fig. 7. In the 55 
image shown, faint diffuse streaks are visible along a*, which 
give some indication of layer stacking disorder, but we have not 
observed any crystals with additional Bragg peaks that might 
indicate significant α2 domains. Since the structure is non-
centrosymmetric, the presence of one stacking fault 60 
corresponding to the inversion-related interlayer arrangement in 
α2 would manifest itself as inversion twinning. We have found 
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some crystals where the Flack parameter refines to zero 
(indicating no inversion twinning) and others where it refines to a 
non-zero value (with suitably small uncertainty) due to inversion 
twinning. Thus, twinning of the α1 structure by incorporation of 
the α2 interlayer arrangement is found to occur, but to date we 5 
have not observed any clear indications of sizeable α2 domains 
within α1 single crystals. A representative structure from our α1 
crystal has been deposited at the Cambridge Crystallographic 
Data Centre (CCDC 1050926). 
 10 
Fig. 7 Reconstructed h1l precession image for a representative crystal of 
α1, aligned as in Fig. 6. Faint streaks are visible in the vertical direction. 
 Numerous crystals of α2 were studied, and these were 
frequently found to be twinned. Using the unit cell established for 
α2 in space group P21/c (a ≈ 17.6, b ≈ 11.9, c ≈ 7.0 Å, β ≈ 97°), 15 
the relationship between the twin domains was established to be a 
180° rotation around the c axis, as indicated in Fig. 6. A typical 
reconstructed precession image for the h1l plane is shown in Fig. 
8. The Bragg reflections of the two twin components are clearly 
separated, and diffuse streaks indicate less ordered regions. The 20 
coincidence of the two lattices for l = 3 is apparent. The twin 
operation corresponds to introduction of the α1 interlayer 
arrangement, but again we have not observed any clear 
indications of Bragg reflections corresponding to sizeable α1 
domains within α2 single crystals. A representative α2 structure 25 
has been deposited at the Cambridge Crystallographic Data 
Centre (CCDC 1050927). 
 
Fig. 8 Reconstructed h1l precession image for a representative crystal of 
α2, aligned as in Fig. 6. Multiple Bragg peaks and diffuse streaks are 30 
evident in the vertical direction. The l = 0 and l = 3 rows appear normal. 
 Finally, it is interesting to note that twinned α2 crystals 
indexed in a standard way commonly indicate a ≈ 52.3 Å (≈ 3 × 
17.6 Å). The reason for this is clear from Figs. 6 and 8. A similar 
long axis was reported by Reck et al.3 in their first determination 35 
of the α1 structure, i.e. the orthorhombic form. This could 
indicate that their α1 crystals contained sizeable domains of the 
α2 structure (i.e. their diffraction pattern resembled the situation 
in Fig. 6). This would amount to intergrowth polymorphism, 
similar to the situation reported for aspirin12,13 and felodipine 40 
form II.14 We have not reproduced any such result to date, but it 
is clear from the polytypic relationship that there is potential for 
such a situation to exist. 
Thermal analysis 
Thermal analysis of bulk α1 and α2 was carried out by differential 45 
scanning calorimetry (DSC), with form I also measured for 
comparison (Fig. 9). Form I shows a single sharp melting 
endotherm with onset 201.2°C. α2 also shows a single sharp 
melting endotherm with onset 198.8°C, which matches well with 
the α2 melting point reported by Michalić et al. (196–198°C).
1 50 
For α1, a first endotherm is seen at 194.8°C, corresponding to 
melting, followed by an exotherm that corresponds to 
crystallization of form I then a subsequent melting endotherm for 
form I. 
 55 
Fig. 9 DSC thermograms for bulk samples of form I, α1 and α2. 
Intermolecular interaction energies 
To obtain an indication of the relative stabilities of α1 and α2, the 
structures of BIYSEH02 (α1) and BIYSEH05 (α2) were energy-
minimized using dispersion-corrected density functional theory 60 
calculations (DFT-D). Details and minimized structures are 
provided in the ESI.† The resulting energies (at 0 K) suggest that 
α2 is moderately more stable than α1, which is nominally 
consistent with the observed melting points. Pairwise 
intermolecular interaction energies were then calculated from the 65 
minimized structures using the PIXEL method (Table 3).24 The 
total potential energy for a molecule in each structure is 
indistinguishable within the expected precision of these 
calculations. However, the distribution of the interactions is 
different. The results are visualised in Fig. 10 using energy-vector 70 
diagrams of the type developed by Shishkin and co-workers,25 
generated using the processPIXEL program.26 Table 3 shows 
sums of the principal stabilising interactions partitioned into 
intra- and interlayer regions. The most striking result is that the 
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pyridyl interlayer region in the α2 structure is calculated to be 
more stabilising than any of the other interlayer regions. This is 
mainly due to a particularly stabilising pairwise interaction 
between inversion-related molecules, with a substantial 
coulombic component originating from C—H···O interactions 5 
involving both SO2 groups (Fig. 11). The corresponding non-
centrosymmetric interaction in the α1 structure involves only one 
such contact and is substantially less stabilising. If the twinning 
in both structures were to be controlled by the intermolecular 
interaction energies, Table 3 implies the following observations: 10 
(i) inversion twinning in the non-centrosymmetric α1 structure is 
most likely to occur at the pyridyl interlayer region; (ii) twinning 
in the α2 structure is most likely to occur at the benzothiazine 
interlayer region. 
Table 3 Interaction energies (kJ·mol–1 per molecule) calculated for α1 and 15 
α2 using the PIXEL method, applied to DFT-D minimized structures. Full 
details are available in the ESI.† 




α1 –153.8 –53.7 –53.4 –38.9 




Fig. 10 Energy-vector diagrams representing the results of PIXEL 
calculations for α1 and α2. The most stabilising interaction in each 
structure is represented by a continuous line joining the centroids of the 
molecules. Other interactions are represented by discontinuous lines, with 
a larger gap indicating a less stabilising interaction.25,26 25 
 
Fig. 11 The most stabilising pairwise intermolecular interaction in the α2 
structure: centrosymmetric, with C—H···O interactions (light blue lines) 
between the pyridyl rings and SO2 groups. 
Conclusions 30 
With this clarification of the structures of piroxicam forms α1 and 
α2, and a specific report of crystallization conditions for both, 
piroxicam has four well-established polymorphs. We have chosen 
to retain the α1/α2 notation of Reck et al. in order to maintain 
consistency with the original work. Where the “form II” label 35 
introduced by Vrečer et al. is seen in the literature, it should be 
considered carefully whether the information in the paper is 
sufficient to distinguish α1 from α2. We have obtained single-
crystal data that show that orthorhombic α1 can exist with only 
minimal twinning/disorder, but single crystals that we have 40 
obtained for monoclinic α2 have frequently been twinned. So far, 
we have not obtained any single crystals that show clear domains 
of both the α1 and α2 polymorphs simultaneously, as would be 
the case for intergrowth polymorphism. 
 This article certainly does not represent the end of the story for 45 
piroxicam polymorphism. We are currently aware of two 
additional crystal structures, one of which we have obtained 
during our solution crystallization experiments, and one of which 
has its unit-cell parameters and simulated PXRD pattern 
reported.27 The latter is a high Z′ form. There has also been a 50 
recent report of a further new form obtained from chloroform 
solution by electrospray methods,28 and we have produced similar 
PXRD patterns in the course of our work. Thus, at least two more 
anhydrous piroxicam crystal structures are already known, and 
there appears to exist one other solid form whose structure is yet 55 
to be established. This will bring the known total (so far) up to 
seven polymorphs, making piroxicam one of the more prolific 
polymorphic pharmaceutical compounds. 
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The polytypic α1 and α2 polymorphs of piroxicam are described and it is 5 
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